345-32-4

Basic information

• Product Name: 5-(TRIFLUOROMETHYL)ISATIN
• Synonyms: 5-(TRIFLUOROMETHYL)ISATIN;BUTTPARK 24\07-39;N-Boc-4-keto-proline methyl ester;Trifluoromethyl isatin;5-(trifluoromethyl)indoline-2,3-dione;5-(Trifluoromethyl)-1H-indole-2,3-dione, 5-(Trifluoromethyl)indolin-2,3-dione
• CAS NO: 345-32-4
• Molecular Formula: C₉H₄F₃NO₂
• Molecular Weight: 215.13
• Product Categories: Indoles and derivatives;Pyrroles & Indoles
• Mol File: 345-32-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 246 °C(Solv: acetic acid (64-19-7))
• Appearance: /
• Density: 1.525 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.48±0.20(Predicted)
• CAS DataBase Reference: 5-(TRIFLUOROMETHYL)ISATIN(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(TRIFLUOROMETHYL)ISATIN(345-32-4)
• EPA Substance Registry System: 5-(TRIFLUOROMETHYL)ISATIN(345-32-4)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 345-32-4(Hazardous Substances Data)

Usage

General Description

5-(Trifluoromethyl)isatin is a chemical compound with the molecular formula C9H5F3NO2. It is a derivative of isatin, which is a heterocyclic organic compound. The "5-(trifluoromethyl)" part of the name refers to the presence of a trifluoromethyl group (-CF3) attached to the fifth carbon atom of the isatin molecule. 5-(TRIFLUOROMETHYL)ISATIN is commonly used in organic synthesis and medicinal chemistry as a building block for the production of pharmaceuticals and agrochemicals. It has been studied for its potential antitumor and antimicrobial properties, making it a subject of interest in biomedical research. Additionally, 5-(trifluoromethyl)isatin has also been explored for its potential as a fluorescent probe for detecting certain biomolecules in biological systems.

Upstream product

• 402-59-5 N-(4-trifluoromethylphenyl)-2-oxyiminoacetamide 
• 141940-37-6 tert-butyl (4-(trifluoromethyl)phenyl)carbamate 
• 455-14-1 4-trifluoromethylphenylamine 
• 91-56-5 indole-2,3-dione 
• 163444-17-5 2-iodo-4-(trifluoromethyl)aniline 
• 1021245-67-9 2-[(4-methoxyphenyl)amino]-N-methylacetamide 
• 1607462-05-4 C₁₄H₁₄F₃NO₅ 

Downstream Products

• 25128-32-9 1H-indole-2,3-dione-5-carboxylic acid 
• 83265-53-6 2-amino-5-(trifluoromethyl)benzoic acid 
• 183720-43-6 (+/-)-3-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-hydroxy-5-(trifluoromethyl)-2H-indol-2-one 
• 897571-13-0 C₁₈H₁₂F₃NO₃ 
• 1314006-02-4 methyl 2-(4-methoxyphenyl)-6-(trifluoromethyl)quinoline-4-carboxylate 
• 1373763-25-7 C₁₈H₁₁F₃N₂O₄S 
• 1373763-19-9 C₁₉H₁₃F₃N₂O₄S 
• 1431875-81-8 6-(trifluoromethyl)-2-(4-phenoxyphenyl)quinoline-4-carboxylic acid 
• 1607461-50-6 C₂₆H₂₆F₃N₅O₂S 
• 1607461-42-6 C₂₂H₁₈F₃N₃O₃S 

Relevant articles and documents

A process for preparing isatin derivatives from substituted aniline

A process for preparing isatin derivatives from substituted aniline is provided. The process includes preparing isatin derivatives with a high yield from substituted aniline shown as a formula II anda carbonylation agent shown as a formula III through acid catalytic oxidation. Compared with traditional processes, the process has characteristics of cheap raw materials, simple and convenient operation, mild reaction conditions, a high product yield, high product purity, wide applicability, and the like, and is environmentally friendly. In addition, the process does not adopt a noble metal catalyst or ligand, so that heavy metal pollution is avoided and the process is suitable for industrial production.

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OR DISORDERS ASSOCIATED WITH MISREGULATED EIF4E

Disclosed herein are compounds, compositions, formulations, kits and methods of treatment useful for treating or preventing one or more hyperproliferative disorders, e.g., cancer or a neurological disease or disorder.

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8- (trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury

Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.